MSB

3.21%

$1.13 mesoblast limited

Ann: Half Year Report and Accounts (including Appendix 4D), page-260

First 260 Last

Share
Profile

Follow
reginaldp

2,891 Posts.

2051

28/02/21

18:01

Post #: 51400599
Share

Originally posted by Southoz: ↑

Come on you guys … Once something is approved it is difficult to withdraw it.

MSB are arguing for approval now … then it will do the adult study. The FDA say do the adult study then we will see.

MSB has never met a primary endpoint in a RCT in 17 years and over a dozen trials. So yes there is time and money … but big risk.

QRX was in the exact same boat. SPL is in it right now. Two years ago SPL received a CRL. It claimed a new trial would be quick and easy. But they wanted to argue the case with the FDA. Two years later … black hole; no new trial - no nothing.

That is unfortunately the most likely outcome here; in two years time people will wondering why MSB just didn’t get on with the job and do the adult study.

In terms of reading the tea leaves about what went on here with the BLA and Ad Com meeting?

I don’t think the FDA changed their minds about anything.

Right at the start MSB were told a single arm trial was potentially approvable … but the design had to be reviewed before being conducted.

MSB failed to have the design reviewed by the FDA and made a blunder with how it derived the historical control group estimate.

MSB were asked to provide further justification for the control group estimate and so they conducted the Mt Sinai study.

The FDA then rejected this. In the eyes of the FDA MSB had done little more than find someone who agreed with their original estimate.

What the FDA wanted was a case-control study with matching at the individual level (not at the group level as MSB had done). Confirmatory – with a proper pre-specified hypothesis that could be tested in a framework that enabled replication.

This misunderstanding about what exactly the FDA wanted by way of further justification from the Mt Sinai study was not picked up because MSB failed to lodge the SAP with the FDA for review.

So yep … that’s the FDA definitely not liking something.

Why would MSB request an Ad Com meeting if it had such a weak case? MSB believed it had a good case. And they were right in a sense - they convinced 9 members of the jury. MSB would have been hopeful that this would sway the judge. As we know it didn’t.

In terms of a sponsor requesting an Ad Com meeting as part of a rolling BLA dispute - someone will have to google it.

But look all imo … and this is water under the bridge – it was months ago and other events have overtaken it somewhat.

And theres another little fish on the fry pan that is distracting me … where I need to jot a few things out. Hopefully in a more coherent fashion.

Expand

That is unfortunately the most likely outcome here; in two years time people will wondering why MSB just didn’t get on with the job and do the adult study.

Or maybe on Tuesday you find out they have funded the adult study?

Reg

MSB Price at posting: $2.46 Sentiment: Hold Disclosure: Held
10 Upvote

0 Great analysis

Reply

Top Stories

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

The winners & losers on market if negative gearing were gone

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

There are more pages in this discussion • 38 more messages in this thread...

First 260 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.13		Change 0.035(3.21%)		Mkt cap ! $1.284B

Open	High	Low	Value	Volume
$1.09	$1.13	$1.07	$3.910M	3.535M

Buyers (Bids)

No.	Vol.	Price($)
2	27197	$1.11

Sellers (Offers)

Price($)	Vol.	No.
$1.13	43578	3

View Market Depth

No.	Vol.	Price($)
4	31763	1.100
2	33264	1.090
2	18897	1.085
2	18926	1.080
1	18000	1.075

Price($)	Vol.	No.
1.130	23400	3
1.135	1090	1
1.140	65000	4
1.145	64500	3
1.150	92314	9

Last trade - 16.10pm 27/09/2024 (20 minute delay)

MSB (ASX) Chart

Ann: Half Year Report and Accounts (including Appendix 4D), page-260

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

ACCC seeks Olam divestments before it can buy Namoi Cotton

The winners & losers on market if negative gearing were gone

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Half Year Report and Accounts (including Appendix 4D), page-260

Top Stories

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

ACCC seeks Olam divestments before it can buy Namoi Cotton

The winners & losers on market if negative gearing were gone

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News